Background Splenectomy is an effective treatment for chronic immune thrombocytopenia (ITP); however, patients' willingness to accept splenectomy is variable.
Introduction
Immune thrombocytopenia (ITP) is a common autoimmune disease characterized by low platelet counts and an increased risk of bleeding. For decades, elective splenectomy has been used as an effective surgical treatment for chronic ITP and is still recommended for patients who fail first-line therapy. 1 However, the optimal timing of splenectomy in the sequence of other ITP treatments is uncertain, and patients are often divided on whether or not they are willing to undergo this procedure. 2, 3 The recent introduction of new medical therapies has made this decision even more complex for patients.
Splenectomy is consistently associated with a durable remission in up to two-thirds of patients 4 and can be performed with minimally invasive techniques. It has been associated with an increased risk of invasive infection estimated at approximately 3%, 5, 6 and given the lack of reliable predictors, it is difficult to determine which patients stand to benefit most. In recent years, rituximab 7 and thrombopoietin receptor agonists 8 have been pursued as potential alternatives to splenectomy; however, unlike splenectomy, responses to these treatments are rarely sustained. [9] [10] [11] The aim of this qualitative descriptive study was to explore how patients with ITP arrive at a decision about whether or not to accept splenectomy when it is recommended to them by their physician. This information should provide context for this complex decision-making process, help understand why patients may be unwilling to accept this effective treatment and direct future research.
Methods

Study design
A qualitative descriptive study was undertaken to explore the phenomenon of decision making around splenectomy and to describe it from the perspective of patients. 12, 13 We used personal one-to-one interviews with open-ended questions to capture the scope of patients' attitudes, beliefs and motivations. This study was approved by the institutional research ethics board, and all participants signed informed consent.
Sampling and recruitment
Patients were recruited from a specialty haematology clinic at an academic teaching hospital in Canada. Patients were eligible if they were 18 years of age or older with chronic primary ITP, had been offered splenectomy as a treatment and were still considered to be splenectomy candidates. Purposive criterion sampling 14 was used to identify patients both for and against splenectomy. All patients were under the shared care of two physicians whose practice patterns were similar and aligned with current ITP guidelines. 1 None of the patients had undergone splenectomy at the time of the interview; those who had agreed to it were awaiting a date for surgery. Primary ITP was defined as a platelet count below 100 9 10 9 /l in the absence of other causes. 15 Eligible patients were identified by their physician and referred to the research coordinator who obtained informed consent. Recruitment continued until no new themes emerged from patient interviews, and no new information was uncovered relating to themes identified during the analysis. 16 
Data collection
The research team included three investigators experienced in qualitative methods and one ITP physician. Interviews were conducted by one of three experienced interviewers. The interview guide, developed by the research team, was used to explore the scope of patients' ideas and experiences. Examples of questions were 'How has having ITP affected your life?' and 'What are your current thoughts about splenectomy as an option for you?' (Fig. 1 ). The interview guide was revised after the first few interviews to capture new ideas in subsequent encounters. Interviews were transcribed verbatim, verified for accuracy by primary interviewers and anonymized. Most interviews lasted 1 h and were conducted in person; when this was not possible, telephone interviews were performed. Demographic data were collected by chart review.
Analysis
Interview transcripts were analysed inductively using a team approach. Investigators independently read the first five transcripts and then met to discuss their content. A list of themes identified from patient interviews and relating to the study objectives was generated by consensus and formed the basis for the initial coding scheme. Transcripts were initially coded by two investigators independently to ensure good agreement, and all subsequent transcripts were coded by either coder. All transcripts were reviewed by each investigator, and themes were inductively derived from the data through discussions at team meetings. This iterative process continued until consensus was achieved, and no new themes emerged. Individual quotes from patients for and against splenectomy were selected to illustrate typical responses, and the diversity of views obtained. NVivo 8 software (QSR International, Cambridge, MA, USA) was used for data analysis and provided an audit trail of the analytical process.
Results
Patient demographics
Between January 2009 and June 2011, a total of 34 splenectomy candidates with ITP were approached for the study and 25 agreed to be interviewed. Of the nine patients who did not consent, one did not speak English; the others declined for unknown reasons. All patients had primary ITP except one with concomitant antiphospholipid antibody syndrome. Recurrent themes became evident after 15 interviews, and all investigators were confident that data saturation was achieved after 25 interviews were completed. Of the 25 patients, 10 (40%) accepted to undergo splenectomy and were awaiting surgery and 15 (60%) refused. Median age of the cohort was 44 years [interquartile range (IQR), 31-59] and 14 (56%) were women. At the time of the interview, median platelet count was 35 9 10 9 /l (IQR, 20-73 9 10 9 /l), median duration of ITP was 48 months (IQR 12-115) and patients had received a median of two prior treatments (IQR, 2-3). Splenectomy was first proposed as a treatment option after a median of 6 months from the time of diagnosis. Patients who refused splenectomy were mostly female, older and had ITP for longer than patients who accepted splenectomy (Table 1) .
Emergent themes about patient preferences regarding splenectomy
Four major themes emerged about patient preference and treatment decision making with respect to splenectomy: (i) patients' perceptions of the impact of ITP on their quality of life, (ii) patients' perceptions of splenectomy as a last resort treatment, (iii) patients' understanding of the rates of splenectomy success and (iv) patients' perceived gaps in knowledge about ITP.
The impact of ITP on quality of life
Patients accepting splenectomy described a negative impact of ITP on their day-to-day lives because of fatigue, anxiety about having a low platelet count, the perceived risk of bleeding or generally feeling unwell. The impact of the disease was also felt in patients' inability to partake in sports, absenteeism from work and the use of regular medications. These patients viewed splenectomy as a chance for them to get back to a regular life. On the other hand, patients refusing splenectomy generally felt that their current clinical situation was not severe enough to warrant surgery. 'It's demanding getting blood tests done all the time and having to worry about it. I was a high school athlete, you know captain of teams… your life really starts to suffer when you can't do things that you're used to doing' (Patient 18, for splenectomy). Splenectomy as a 'last resort'
ITP patients described a consistent pattern in their decision-making process, which evolved as their illness progressed from diagnosis, to medical treatment(s), to relapse or treatment failure (s) over a period of many weeks or months. On this trajectory, many patients came to view splenectomy as something that would only be tried if all other treatments failed. Patients refusing splenectomy were reluctant to accept it because of a perceived message they picked up from their physicians (whether intended or not) that there were no other options.
'He had said to me: 'well, we can do this and this and this and this and this, and then if none of that works we can try a splenectomy'' (Patient 5, against splenectomy).
'I was told that that would be … a complete last resort' (Patient 13, against splenectomy).
'I'm afraid if it doesn't work for me like nothing else has been working… then I'm left with no spleen and no other options' (Patient 9, against splenectomy).
The concept of 'permanency' emerged as a subtheme among splenectomy refusers who felt put-off by the notion of the permanent loss of an otherwise healthy organ.
'I personally feel that if a person has a spleen then it's there for a reason' (Patient 16, against splenectomy).
Patients' understanding of the rates of splenectomy success
Patients recalled being quoted splenectomy success rates as low as 50% and as high as 70%. However, they interpreted these group-level statistics in a variety of ways, making them personally meaningful to their own decision-making task. Patients often used heuristics, especially gambling analogies, to relate the rates of treatment success and failure to day-to-day experiences, and the same statistics were used to justify a decision for and against splenectomy. ' Basically it's a gamble and you know I'm not a gambling type…if you have a 50-50 situation that's not a good gamble as far as I'm concerned' (Patient 3, against splenectomy). 'I'm not much of a gambler but the odds seem pretty good' (Patient 21, for splenectomy).
'He presented 60% as being a high number; and I see 60% as being a low number… when I start spouting blood all over the place I may come back and say well 60% is looking good now' (P23, against splenectomy).
Other factors, including the presence or absence of morbidities from bleeding and future bleeding risk, contributed to patient choice.
Knowledge gaps about the ITP disease
The diagnosis of ITP came as a surprise to most patients, because it was typically discovered incidentally as a result of a low platelet count on a blood test that was done for other reasons or because of minor symptoms only such as bruising. Patients described feeling frightened when they were first told of their diagnosis, which was generally portrayed as overly serious or life-threatening; however, over the course of time, patients became accustomed to their illness and its often modest clinical severity. This experience made splenectomy refusers somewhat sceptical. ' It was a shock. My family physician sent me for a cholesterol test… and then he says 'by the way, your platelets are low'. I thought he had the wrong patient' (Patient 6, against splenectomy). 'In the beginning…they scared me silly… and they said you're in such critical condition, you could start hemorrhaging from your brain. And I thought, ok I'm going to die… And once I saw that it was 6 months later and I was still feeling hale and hearty I decided that… I must not be so bad. I just got used to it afterwards but the first 6 months were traumatic' (Patient 16, against splenectomy).
'I do need somebody to say to me 'this is very serious, I really believe you need to get this done'. If he said that then I would consider it. But because nobody has ever said that to me I figure it's not that important' (Patient 15, against splenectomy).
Patients also expressed frustration with their lack of knowledge of the cause of ITP. In the absence of facts, patients developed their own interpretations of the cause of their disease, for example, having acquired it from exposure to 'bugs', childhood measles or from spleen damage after remote trauma. Patients were dissatisfied with the lack of information they had received about ITP, treatment alternatives and a general lack of familiarity with ITP in general compared with other more prevalent diseases. Personal encounters with other patients in common waiting areas also influenced patients' decisions, mostly negatively. Encounters were more likely to occur with patients who had failed splenectomy, as opposed to patients who had responded favourably and no longer required on-going care. ' One thing that did sway my decision…was actually sitting in a waiting room… she was saying how she had low platelets and she did a splenectomy and it was even worse after her splenectomy' (Patient 16, against splenectomy).
The manner in which information was presented to patients by their physicians was also identified as an influence on treatment choice. 'I think it was presented in a little bit of a laissez-faire sort of way, this is easy, happens all the time, it's a quick surgery, you're out in 1 day… it almost sounded too easy' (Patient 12, against splenectomy).
Discussion
While splenectomy is an effective treatment for chronic ITP, 4 the uptake of splenectomy by patients is variable. This variability is due in part to a lack of evidence-based guidance on the timing of splenectomy with respect to other therapies and has led to polarized views about this treatment. We identified four themes influencing patients' decision to accept or refuse splenectomy relating to patients' perceptions of their disease and its severity, and the adequacy of physician-patient communication about outcomes. Defining the informational needs of patients and the best ways of meeting them, for example, through the use of decision aids or other tools, 17 may facilitate treatment decision making in this area.
Patients who accepted splenectomy were influenced by negative experiences of the impact of their disease on their lives, a desire to get back to 'day-to-day life' and an overall frustration with their current condition. Such patients generally did not cite abnormally low platelet counts per se as the motivation behind their treatment choice, which suggests that the illness experience and perceived symptoms were more important to patients in triggering a move towards splenectomy. This is in contrast to recommended treatment indications, which is largely driven by platelet count criteria. 1 The portrayal of splenectomy as a last resort was cited by patients as a negative influence, suggesting that while it may be reasonable to delay splenectomy until later in the disease course, discussions about this and other options should occur early.
In interpreting probabilities of risks and benefits of splenectomy, patients participated in a form of lay risk analysis to make these statistics personally meaningful; however, the statistical meaning of probabilities refers to average outcomes for groups and not for individuals. 18, 19 Physicians must be cognizant of this dissociation and communicate treatment risks and benefits in a way that will improve understanding of probabilities, including their inherent limitations in estimating individual treatment outcomes. We found that the language used by clinicians influenced patients' interpretation of the information presented, consistent with findings from other studies on framing effects. 20 Patient preferences in ITP can be viewed within the context of conceptual models of treatment decision making that include the patient as an active participant, such as the informed and shared decision-making models. 21 Patient perceptions of gaps in their knowledge of the ITP disease and the efficacy of treatments may impede more widespread use of these participatory decision-making models, which have been shown to be important in other patient groups. 22 Previous studies have addressed the issue of decision making in the context of other elective surgical procedures where several treatment alternatives were available. A study of carotid endarterectomy for stroke prevention found that key factors influencing treatment choice were uncertainty of outcomes, assessment of risk, the potential for regret, patients' and surgeon's role in the decision-making process and the magnitude of potential gains. 23 In a study of elderly patients unwilling to undergo total joint arthroplasty as a treatment for arthritis, lack of information from health-care providers and a reluctance to participate actively in decision making influenced treatment choices. 24 Similarly, our study sought to uncover reasons why patients refused an effective therapy and identified themes relating to physician-patient communication and lack of knowledge about the disease. Treatment decision making in ITP is further complicated by its relatively low prevalence and the lack of a general familiarity with the condition.
Strengths of this study include the novel application of qualitative methods to this field of haematology, an experienced team of qualitative researchers and the use of rigorous methods to investigate patient preferences. 25 An exploratory descriptive design was used because no previous research had been conducted in this area. Timing of this study coincided with the availability of other medical therapies for ITP, including the thrombopoietin receptor agonists, thus reflecting the current practice environment. Limitations of this study were the single centre design, which may not reflect patterns of practice across geographical regions 26 and our inability to describe the evolution of treatment preferences over time from single interviews. We recognize that patient choice may be highly influenced by physicians; however, the impact of the physician in this study would be expected to be similar across patients who were cared for jointly by 2 ITP physicians working in the same clinic with similar practice patterns.
The themes uncovered in this study provide a context for understanding patient choice with respect to splenectomy and represent a first step towards developing an individualized approach to ITP management based on patient preference. Awareness of the informational needs of ITP patients focusing on communicating benefits, risks and alternatives to splenectomy will facilitate this complex decision-making process for patients.
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